Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment
Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a…
Continue Reading